Skip to main content

Guro Løvik Goll

Senior researcher
https://orcid.org/0000-0002-8506-725X

See Google Scholar profile

See publications in PubMed

Education

Can.med, Faculty of Medicine, University of Oslo (1995)
Doctoral degree at the Faculty of Medicine, University of Oslo (2001)

Position

Senior researcher, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
Senior physician in rheumatology, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital

Field of interest

Advanced drug treatment of inflammatory rheumatic disease
Biomarkers
Drug monitoring
Biosimilar medicines
Synovial biopsies
Autoimmunity
Vaccine response

Email

Telephone

visiting address

Diakonhjemmet hospital
Diakonveien 12
0370 Oslo

Postal address

Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP2 - PPhenotyping for personalized medicine

BIKE

Biopsies of synovitis in the knee joint from patients with RA and OA

Project Manager:

Hilde Berner Hammer

WP2 - PPhenotyping for personalized medicine

BioTest

Experimental precision medicine

Project Manager:

Guro Løvik Goll

WP1 - Optimized medical interventions

NOR SWITCH

Switching from the original preparation to a biosimilar medicine to patients with inflammatory disease of the joints, intestines or skin.

Project Manager:

Tore K. Kvien

WP2 - PPhenotyping for personalized medicine

Nor-vaC

Immunological response to COVID-19 vaccine in patients on immunosuppressive treatment

Project Manager:

Guro Løvik Goll

WP1 - Optimized medical interventions

SQUEEZE

Maximizing the effect of prescription drugs in rheumatoid arthritis

Project Manager:

Espen A. Haavardsholm

Publications

Publications taken from the National Science Archive (NVA):

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials

Marthe Kirkesæther Brun, Johanna Gehin, Kristin Reine Hammersbøen, David Warren, Rolf Klaasen, Joseph Sexton

The Lancet Rheumatology

2024

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

Hassen Kared, Ingrid Jyssum, Amin Alirezaylavasani, Ingrid Marie Egner, Trung The Tran, Lisa Tietze

Frontiers in Immunology

2024

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

Hilde Sofie Sager Ørbo, Kristin Reine Hammersbøen, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen

RMD Open

2024

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

Asia-Sophia Fumika Michaela Wolf, Kristin Reine Hammersbøen, Hilde Sofie Sager Ørbo, Sabin Bhandari, Guri Solum, Ingrid Fadum Kjønstad

EBioMedicine

2024

Therapeutic serum level for adalimumab in rheumatoid arthritis: exploratory analyzes of data from a randomized phase III trial

Johanna Gehin, Rolf Klaasen, Eirik Kristianslund, Ingrid Jyssum, Joseph Sexton, David Warren

RMD Open

2024

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Ingrid Jyssum, Johanna Gehin, Joseph Sexton, Eirik Kristianslund, Yi Hu, David Warren

Rheumatology

2023

Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway

Guro Løvik Goll, Tore Kristian Aaserud Kvien

Expert Opinion on Biological Therapy

2023

Hybrid and SARS-CoV-2 vaccine immunity in kidney transplant recipients

Hassen Kared, Amin Alirezaylavasani, Kathrine Persgård Lund, Adity Chopra, Lisa Tietze, Taissa de Matos Kasahara

EBioMedicine

2023

Cytokine Patterns as Predictors of Antibiotic Treatment Effect in Chronic Low Back Pain with Modic Changes: Subgroup Analyzes of a Randomized Trial (AIM Study)

Lars Christian Haugli Bråten, Elisabeth Gjefsen, Kristina Gervin, Are Hugo Pripp, Jan Sture Skouen, Elina Iordanova Schistad

Journal of Pain Research

2023

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases

Marthe Kirkesæther Brun, Kristin Reine Hammersbøen, Marte Kathrine Viken, Grethe-Elisabeth Stenvik, Rolf Klaasen, Johanna Gehin

Journal of Internal Medicine

2023

Longitudinal changes of serum cytokines in patients with chronic low back pain and Modic changes

Elisabeth Gjefsen, Kristina Gervin, Lars Christian Haugli Bråten, Guro Løvik Goll, Hans Christian Aass, Elina Iordanova Schistad

Osteoarthritis and Cartilage

2023

Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type

Kristin Kaasen Jørgensen, Marte Lie Høivik, Adity Chopra, Jurate Saltyte Benth, Petr Ricanek, Bjørn Allan Moum

Scandinavian Journal of Gastroenterology

2023

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

Charlotte LM Krieckaert, Astrid Van Tubergen, Johanna Elin Gehin, Borja Hernández-Breijo, Guillaume Le Mélédo, Alejandro Balsa

Annals of the Rheumatic Diseases

2022

Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis

Shrikant Kolan, Gaoyang Li, Franco Grimolizzi, Joseph Sexton, Tore Kristian Kvien, Guro Løvik Goll

Frontiers in Pharmacology

2022

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

Kristin H. Bjørlykke, Hilde Sofie Sager Ørbo, Anne Therese Tveter, Ingrid Jyssum, Joseph Sexton, Trung Tran

The Lancet Rheumatology

2022

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Ingrid Egeland Christensen, Trung Tran

RMD Open

2022

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Ingrid Egeland Christensen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Trung Tran, Siri Mjaaland

BMC Medicine

2022

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, Meghna Jani, Nils Bolstad, Silje Watterdal Syversen

BioDrugs

2022

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

Kristin Reine Hammersbøen, Jørgen Jahnsen, Jørn Brynskov, Pauliina Molander, Michael Eberhardson, Loà G. Davidsdottir

Scandinavian Journal of Gastroenterology

2022

Risk factors for anti-drug antibody formation to infliximab: Secondary analyzes of a randomized controlled trial

Marthe Kirkesæther Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, Joseph Sexton, Johanna Elin Gehin, Øystein Sandanger

Journal of Internal Medicine

2022

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Trung Tran, Joseph Sexton, Sella Aarrestad Provan

Arthritis & Rheumatology

2022

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Ingrid Jyssum, Hassen Kared, Trung Tran, Anne Therese Tveter, Sella Aarrestad Provan, Joseph Sexton

The Lancet Rheumatology

2021

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.

Johanna Elin Gehin, Silje Watterdal Syversen, David Warren, Guro Løvik Goll, Joseph Sexton, Nils Bolstad

RMD Open

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, Marthe Kirkesæther Brun, Øystein Sandanger, Kristin Reine Hammersbøen

Journal of the American Medical Association (JAMA)

2021

Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia

Sverre Holm, Hassen Kared, Annika Elisabet Michelsen, Xiang Yi Kong, Tuva Børresdatter Dahl, Nina Haagenrud Schultz

European Heart Journal

2021

Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study

Johanna Elin Gehin, David Warren, Silje Watterdal Syversen, Elisabeth Lie, Joseph Sexton, Liz Paucar Loli

Scandinavian Journal of Rheumatology

2021

Macrophage migration inhibitory factor: A potential biomarker for chronic low back pain in patients with Modic changes

Elisabeth Gjefsen, Kristina Gervin, Guro Løvik Goll, Lars Christian Haugli Bråten, Monica Wigemyr, Hans Christian Dalsbotten Aass

RMD Open

2021

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort

Johanna Elin Gehin, Rolf Klaasen, ELLEN SAUAR NORLI, David Warren, Silje Watterdal Syversen, Guro Løvik Goll

Rheumatology International

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Øystein Sandanger, Joseph Sexton, Inge Christoffer Olsen

Journal of the American Medical Association (JAMA)

2021

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Øystein Sandanger, Johanna Elin Gehin

Trials

2020

The effect of infliximab in patients with chronic low back pain and Modic changes (the BackToBasic study): study protocol of a randomized, double blind, placebo-controlled, multicenter trial

Elisabeth Gjefsen, Lars Christian Haugli Bråten, Guro Løvik Goll, Monica Wigemyr, Nils Bolstad, Morten Valberg

BMC Musculoskeletal Disorders

2020

Efficacy and safety of CT-P13 in inflammatory bowel disease after switching from originator infliximab: Exploratory analyzes from the NOR-SWITCH main and extension trials

Kristin Kaasen Jørgensen, Guro Løvik Goll, Joseph Sexton, Nils Bolstad, Inge Christoffer Olsen, Øivind Wessel Asak

BioDrugs

2020

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Johanna Elin Gehin, Guro Løvik Goll, David John Warren, Silje Watterdal Syversen, Joseph Sexton, Eldri Kveine Strand

Arthritis Research & Therapy

2019

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial

Guro Løvik Goll, Kristin Kaasen Jørgensen, Joseph Sexton, Inge Christoffer Olsen, Nils Bolstad, Espen A. Haavardsholm

Journal of Internal Medicine

2019

Biological drugs in rheumatology

Guro Løvik Goll

Norwegian Pharmaceutical Journal

2018

Confiance des rhumatologues quant au passage a un biosimilaire

Guro Løvik Goll, Espen A. Haavardsholm, Tore Kristian Kvien

Revue du Rhumatisme (Edition Francaise)

2018

Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons

Till Uhlig, Guro Løvik Goll

Rheumatology

2017

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll, Merete Lorentzen, Nils Bolstad, Espen A. Haavardsholm

The Lancet

2017

Interleukin-15 Induces Interleukin-17 Production by Synovial T Cell Lines from Patients with Rheumatoid Arthritis

Eirik Hornes Halvorsen, Erlend Strønen, Hilde Berner Hammer, Guro Løvik Goll, Ludvig Magne Sollid, Øyvind Molberg

Scandinavian Journal of Immunology

2011

The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis

Diane van der Woude, Silje Watterdal Syversen, Ellen IH van der Voort, Kirsten N. Verpoort, Michael PM van der Linden, Annette HM van der Helm-van Mil

Annals of the Rheumatic Diseases

2010

Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs

Silje Watterdal Syversen, Espen A. Haavardsholm, Pernille Helen Bøyesen, Guro Løvik, Per Ivar Brachel Gaarder, Désirée van der Heijde

Annals of the Rheumatic Diseases

2010

Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study

Silje Watterdal Syversen, D van der Heijde, Robert Landewé, Benedicte Alexandra Lie, Sigrid Ødegård, Till Uhlig

Annals of the Rheumatic Diseases

2010